Cargando…
A luminescence-based protocol for assessing fructose metabolism via quantification of ketohexokinase enzymatic activity in mouse or human hepatocytes
Ketohexokinase (KHK) catalyzes the first step of fructose metabolism. Inhibitors of KHK enzymatic activity are being evaluated in clinical trials for the treatment of non-alcoholic fatty liver disease (NAFLD) and diabetes. Here, we present a luminescence-based protocol to quantify KHK activity. The...
Autores principales: | Park, Se-Hyung, Helsley, Robert N., Noetzli, Leila, Tu, Ho-Chou, Wallenius, Kristina, O’Mahony, Gavin, Boucher, Jeremie, Liu, Jianming, Softic, Samir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361265/ https://www.ncbi.nlm.nih.gov/pubmed/34409309 http://dx.doi.org/10.1016/j.xpro.2021.100731 |
Ejemplares similares
-
Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction
por: Gutierrez, Jemy A., et al.
Publicado: (2021) -
Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis
por: Shepherd, Emma L., et al.
Publicado: (2020) -
Ketohexokinase-mediated fructose metabolism is lost in hepatocellular carcinoma and can be leveraged for metabolic imaging
por: Tee, Sui Seng, et al.
Publicado: (2022) -
GLUT5 (SLC2A5) enables fructose-mediated proliferation independent of ketohexokinase
por: Liang, Roger J., et al.
Publicado: (2021) -
Ketohexokinase-dependent metabolism of cerebral endogenous fructose in microglia drives diabetes-associated cognitive dysfunction
por: Li, Yansong, et al.
Publicado: (2023)